Can Replacing CA125 with HE4 in Risk of Malignancy Indices 1–4 Improve Diagnostic Performance in the Presurgical Assessment of Adnexal Tumors?

Table 2

Distribution of malignant adnexal masses.

Pathology	Number of patients (%)
Ovarian serous tumors	23 (44.23%)
Ovarian endometrioid tumors	11 (21.15%)
Ovarian borderline serous tumors	5 (9.62%)
Ovarian mucinous tumors	3 (5.77%)
Ovarian clear-cell tumors	3 (5.77%)
Oviduct malignancy	2 (3.85%)
Ovarian borderline mucinous tumors	2 (3.85%)
Ovarian sarcoma	1 (1.92%)
Ovarian folliculoma	1 (1.92%)
Ovarian germinal tumor	1 (1.92%)